In this interview we speak to Keith Kaye, from the University of Michigan (MI, USA) about the RESTORE-IMI 2 study, its results and why ICU patients represent an unmet need.
In this interview we speak to Michael Bachman (University of Michigan MI, USA) about his research on the factors involved in Klebsiella colonization and infection, and whether these could be used to stratify high-risk patients in the future.
New research shows that hydrogen peroxide released by Streptococcus pneumoniae inhibits key components of the innate immune system. This contributes to the successful pathogen colonization of the host and causes pneumonia.
Take a look at this month’s industry headlines including an FDA approval for Zebraxa, new…
A global genomic survey of Streptococcus pneumoniae has identified 621 strains across 50 countries and has highlighted how the bacteria can evolve in response to vaccination.
To round up 2018, we asked our Expert panel to choose their top papers from across the year. Here, you can discover the articles they selected and read about and the reasons why!
The US FDA has approved Paratek Pharmaceuticals’ antibiotic Nuzyra™ (omadacycline) for the treatments of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Merck’s antibiotic ZERBAXA® (ceftolozane and tazobactam) has met its primary endpoint of non-inferiority compared with meropenem in a Phase III trial of patients with hospital-acquired and ventilator-associated bacterial pneumonia.
An isolate of colistin-heteroresistant, carbapenem-resistant, hypervirulent/hypermucoviscous Klebsiella pneumoniae has been identified in the USA.
In this interview, we speak to Dr. Bryan Kraft, an Assistant Professor of Medicine at Duke University, about his research into carbon monoxide as a potential therapy to treat ARDS and the clinical trial for this therapy that is currently underway.
